Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease.

Peter A WijeratneEileanoir B JohnsonE Ann YehLeon AksmanSarah GregoryHans J JohnsonGovinda R PoudelAmrita MohanCristina SampaioNellie Georgiou-KaristianisJane S PaulsenSarah J TabriziRachael I Scahillnull nullDaniel C Alexander

Published in: Annals of neurology (2020)

Our findings provide the first cross-study validation of structural imaging markers in HD, supporting the use of these measurements as endpoints for both observational studies and clinical trials. ANN NEUROL 2020;87:751-762.

Keyphrases

clinical trial
high resolution
cross sectional
randomized controlled trial
open label
photodynamic therapy
phase ii